Type of Diabetes Mellitus and the Odds of Gleason Score 8 to 10 Prostate Cancer
Creators
- 1. Harvard Radiation Oncology Program, Boston, MA (United States)
- 2. Department of Statistics, University of Connecticut, Storrs, CT (United States)
- 3. Prostate Cancer Foundation of Chicago, Westmont, IL (United States)
- 4. Department of Radiation Oncology, 21 Century Oncology, Inc., Fort Myers, FL (United States)
- 5. Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA (United States)
Description
Purpose: It has been recently shown that diabetes mellitus (DM) is significantly associated with the likelihood of presenting with high-grade prostate cancer (PCa) or Gleason score (GS) 8 to 10; however, whether this association holds for both Type 1 and 2 DM is unknown. In this study we evaluated whether DM Type 1, 2, or both are associated with high-grade PCa after adjusting for known predictors of high-grade disease. Methods and Materials: Between 1991 and 2010, a total of 15,330 men diagnosed with PCa and treated with radiation therapy were analyzed. A polychotomous logistic regression analysis was performed to evaluate whether Type 1 or 2 DM was associated with odds of GS 7 or GS 8 to 10 compared with 6 or lower PCa, adjusting for African American race, age, prostate-specific antigen (PSA) level, and digital rectal examination findings. Results: Men with Type 1 DM (adjusted odds ratio [AOR], 2.05; 95% confidence interval [CI], 1.28–3.27; p = 0.003) or Type 2 DM (AOR, 1.58; 95% CI, 1.26–1.99; p < 0.001) were significantly more likely to be diagnosed with GS 8 to 10 PCa compared with nondiabetic men. However this was not true for GS 7, for which these respective results were AOR, 1.30; 95% CI, 0.93–1.82; p = 0.12 and AOR, 1.13; 95% CI, 0.98–1.32; p = 0.10. Conclusion: Type 1 and 2 DM were associated with a higher odds of being diagnosed with Gleason score 8 to 10 but not 7 PCa. Pending validation, men who are diagnosed with Type I DM with GS 7 or lower should be considered for additional workup to rule out occult high-grade disease.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2011.07.003Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2011.07.003;
- PII
- S0360-3016(11)03006-9;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 82
- Journal Issue
- 3
- Journal Page Range
- p. e463-e467
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44016510
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANTIGENS; DIABETES MELLITUS; MEN; NEOPLASMS; PROSTATE; RADIOTHERAPY; RECTUM; REGRESSION ANALYSIS; VALIDATION
- Descriptors DEC
- ANIMALS; BODY; DIGESTIVE SYSTEM; DISEASES; ENDOCRINE DISEASES; GASTROINTESTINAL TRACT; GLANDS; INTESTINES; LARGE INTESTINE; MALE GENITALS; MALES; MAMMALS; MAN; MATHEMATICS; MEDICINE; METABOLIC DISEASES; NUCLEAR MEDICINE; ORGANS; PRIMATES; RADIOLOGY; STATISTICS; TESTING; THERAPY; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.